Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.

Advertisements

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI Trial Phase 2a Treatment-Naïve and Treatment-Experienced.

Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta- analysis Eline J.C.A. Kamp, John S. Kane, Alexander C. Ford Clinical Gastroenterology.

Sofosbuvir-Velpatasvir-Voxilaprevir in GT 3 and Cirrhosis POLARIS-3

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial

Volume 149, Issue 6, Pages (November 2015)

Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving Jagpreet Chhatwal, Tianhua He, Chin Hur, Maria.

Thrombocytopenia With Abnormal Liver Function Tests

Noncardiac Chest Pain Clinical Gastroenterology and Hepatology

Chronic Hepatitis C Therapy: Changing the Rules of Duration

Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus– Associated Cryoglobulinemia Treated With Direct-Acting Antivirals

Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis

Nathalie Adda, Doug J. Bartels, Linda Gritz, Tara L

Covering the Cover Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

Coordinating Care in Patients With Cirrhosis

Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non- Cirrhotic Patients: A Societal Perspective Gihan Hamdy Elsisi, MSc, PhD,

Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin Jean–François Rossignol, Asem Elfert,

A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus Amit G. Singal, Michael.

Daclatasvir + Peg/RBV in Treatment-Naïve Genotype 4 COMMAND-4 Study

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

Phase 2 Treatment Naïve and Treatment Experienced

Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3

Fasiha Kanwal, MD, MSHS, Hashem B. El-Serag, MD, MPH

Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse

Volume 155, Issue 5, Pages e2 (November 2018)

Jean-Michel Pawlotsky Gastroenterology

No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening Brianna L. Norton,

Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel

Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B Jeong Han Kim, So Young Kwon, Young Sok.

Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C Pamela S. Belperio, Elizabeth.

Volume 138, Issue 1, Pages (January 2010)

Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H

Jessica L. Mellinger, Michael L. Volk

Interpreting Hepatitis B Surface Antigen Levels: Useful Clinical Test or Just Another Confusing Assay? Brian J. McMahon, MD, Brenna C. Simons, PhD Clinical.

Bisphosphonates Are Associated With Reduced Risk of Colorectal Cancer: A Systematic Review and Meta-analysis Siddharth Singh, Abha Goyal Singh, Mohammad.

The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related.

Why We Should Be Willing to Pay for Hepatitis C Treatment

Issue Highlights Clinical Gastroenterology and Hepatology

Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir Zobair.

Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients Vincent G. Bain, Kelly D.

Volume 68, Issue 4, Pages (April 2018)

Volume 142, Issue 6, Pages (May 2012)

Rafael Esteban, Maria Buti Gastroenterology

Histologic Changes in Liver Tissue From Patients With Chronic Hepatitis B and Minimal Increases in Levels of Alanine Aminotransferase: A Meta-analysis.

Chronic Hepatitis C Therapy: Changing the Rules of Duration

Brendan Campbell, Benny Liu, Taft Bhuket, Robert J. Wong

Peter Bytzer Clinical Gastroenterology and Hepatology

Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease Markus.

Lisa I. Backus, Derek B. Boothroyd, Barbara R

Patient-Reported Outcomes of Cirrhosis

Genetic Factors and Hepatitis C Virus Infection

Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Siddharth.

Alan Bonder, MD, Nezam H. Afdhal, MD

Probiotics Prevent Hepatic Encephalopathy in Patients With Cirrhosis: A Randomized Controlled Trial Manish Kumar Lunia, Barjesh Chander Sharma, Praveen.

Alessio Aghemo, Maria Francesca Donato Gastroenterology

Thrombocytopenia With Abnormal Liver Function Tests

Christos Konstantakis, Maria Karamesini, Christos Triantos

Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States Zobair M. Younossi, Maria Stepanova

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

A 27-Year-Old Woman With Constipation: Diagnosis and Treatment

Volume 147, Issue 6, Pages (December 2014)

Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction? Masaru Enomoto, Yoshiki Murakami,

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized,

Fasiha Kanwal, Tuyen Hoang, Timothy Chrusciel, Jennifer R

Presentation transcript:

Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis Floor A.C. Berden, Bryan R.R.Z. Aaldering, Hans Groenewoud, Joanna IntHout, Wietske Kievit, Joost P.H. Drenth Clinical Gastroenterology and Hepatology Volume 15, Issue 3, Pages 349-359 (March 2017) DOI: 10.1016/j.cgh.2016.10.034 Copyright © 2017 AGA Institute Terms and Conditions

Figure 1 Study selection flow chart summarizing the selection and identification of trials and studies. GT3, genotype 3; SVR12/24, sustained virologic response at 12 or 24 weeks after cessation of treatment. Clinical Gastroenterology and Hepatology 2017 15, 349-359DOI: (10.1016/j.cgh.2016.10.034) Copyright © 2017 AGA Institute Terms and Conditions

Figure 2 Networks of studies. Evidence network of all DAA-based regimens studied in chronic hepatitis C genotype 3 patients. The thickness of the lines represents the number of studies (connecting lines) or the total number of patients studied (box lines). Within the box, the DAA combination with the duration of treatment (12, 16, or 24 weeks) is visible. Gray regimens are selected for ranking. DCV, daclatasvir; LDV, ledipasvir; OBV, ombitasvir; PR, peginterferon and ribavirin; PTV, paritaprevir/ritonavir; RBV, ribavirin; SOF, sofosbuvir; TPR, telaprevir; 12, 12 weeks; 16, 16 weeks; 24, 24 weeks; VEL, velpatasvir 100 mg; VEL(25), velpatasvir 25 mg. Clinical Gastroenterology and Hepatology 2017 15, 349-359DOI: (10.1016/j.cgh.2016.10.034) Copyright © 2017 AGA Institute Terms and Conditions

Figure 3 Estimated SVR rates per regimen. (A) The mean estimated probability on SVR per regimen with 95% CrI. The SVR rates are estimated for patients without cirrhosis. (B) The mean estimated probability on SVR per regimen with 95% CrI. The SVR rates are estimated for patients with cirrhosis. DCV, daclatasvir; LDV, ledipasvir; OBV, ombitasvir; PR, peginterferon and ribavirin; PTV, paritaprevir/ritonavir; RBV, ribavirin; SOF, sofosbuvir; TPR, telaprevir; 12, 12 weeks; 16, 16 weeks; 24, 24 weeks; VEL, velpatasvir. Clinical Gastroenterology and Hepatology 2017 15, 349-359DOI: (10.1016/j.cgh.2016.10.034) Copyright © 2017 AGA Institute Terms and Conditions